Morgan Stanley Raises CME Price Target to $337

Morgan Stanley has reaffirmed its Overweight rating on CME Group Inc. (CME), raising its price target from $330 to $337 on October 9, 2026. This change reflects Morgan Stanley's positive outlook on the financial services company, which operates trading platforms for futures and options contracts worldwide.

Other Institutional Activity in CME Group

Several other institutional investors have also made adjustments to their positions in CME Group. Blackrock Inc. reduced its holdings by 880,512 shares, now holding 30,566,342 shares valued at approximately $8.98 billion. Vanguard Capital Management LLC added 294,430 shares, increasing its total to 23,661,856 shares worth about $6.95 billion. State Street Corporation grew its stake by 290,606 shares, ending with 16,346,170 shares valued at around $4.80 billion. Morgan Stanley, which is already a significant holder, increased its shares by 321,702, totaling 9,728,195 shares worth about $2.86 billion. Geode Capital Management, LLC also increased its position by 124,398 shares, now holding 9,271,309 shares valued at around $2.72 billion.

CME Group Inc. Stock Up 0.3%

CME Group's shares are currently trading around $290.33, which places them 13.8% below the new price target set by Morgan Stanley. This comes as the stock is navigating the financial market's fluctuations, reflecting a stable position compared to its peers. The recent trading levels highlight a cautious investor sentiment, especially with the upcoming earnings report.

Recent Earnings

CME Group reported a trailing twelve-month revenue of approximately $6.76 billion and earnings per share (EPS) of $11.79. The company has demonstrated a net margin of 63.4% and a return on equity (ROE) of 15.8%. The next earnings date is set for October 21, 2026, which will be closely watched by investors for further insights into the company's performance.

Dividend

CME Group pays an annual dividend of $5.20 per share, with a high payout ratio of 95.4%. This indicates a strong commitment to returning value to shareholders, although it also suggests that the company is reinvesting a smaller portion of its earnings back into the business.

Insider Buying and Selling at CME Group Inc.

Insider transactions at CME Group reveal a mix of buying and selling activity. On June 25, 2026, Director William R. Shepard bought 339 shares at an average price of $230.57, totaling about $78,186. CEO Terrence A. Duffy sold 15,000 shares on September 10, 2026, valued at approximately $4.12 million. Director Elizabeth A. Cook sold 500 shares on September 14, 2026, at an average price of $280.11 for a total of around $140,055. Additionally, on September 25, 2026, William R. Shepard purchased 292 shares at an average price of $268.76, valued at about $78,626.

Analysts Set New Price Targets

On October 2, 2026, Wells Fargo initiated coverage on CME Group with an Overweight rating and a price target of $301.00. On October 5, 2026, UBS maintained a Neutral rating and increased its target from $260.00 to $270.00. TD Cowen also maintained its Buy rating, raising the target from $292.00 to $300.00. Barclays kept an Equal-Weight rating with a target increase from $270.00 to $281.00. The consensus among analysts shows a positive outlook with varying price targets reflecting differing expectations.

About CME Group

CME Group Inc. operates global markets for trading futures and options contracts. It provides a wide range of products including interest rates, equity indexes, foreign exchange, and commodities. The company's ability to adapt to market demands and maintain regulatory compliance is crucial for its continued success, especially as it faces competition in the financial services sector.

Bottom Line

Investors should keep an eye on CME Group as it approaches its next earnings report on October 21, 2026. With Morgan Stanley's recent target increase and other analysts maintaining their ratings, the outlook remains positive amid market fluctuations. The ongoing insider activity also provides insights into the confidence of company leadership in its future performance.